AC Immune shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and $8 price target.
Portfolio Pulse from Benzinga Newsdesk
AC Immune shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and $8 price target.
May 31, 2024 | 3:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune shares are experiencing an upward trend following BTIG's initiation of coverage with a Buy rating and an $8 price target.
BTIG's initiation of coverage with a Buy rating and a specific price target of $8 is a strong positive signal for investors, likely driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100